Advanz Pharma Nordic Capital Nordic Capital 40900000 2021 20210729 competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
The Competition and Markets Authority (CMA) found that from 2009 until 2017 the pharmaceutical company Advanz charged excessive and unfair prices for supplying liothyronine tablets which are used to treat thyroid hormone deficiency. The agency also fined two private equity firms, HGCapital and Cinven, that previously owned parts of the business. agency action UK-CMA Competition and Markets Authority Sweden privately held private equity (including portfolio companies) private equity (including portfolio companies) https://www.gov.uk/government/news/cma-fines-pharma-firm-over-pricing-of-crucial-thyroid-drug UK21-158
Focus Pharmaceuticals Limited and Focus Pharma Holdings Limited Nordic Capital Nordic Capital 549343 2022 20220203 competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation. agency action UK-CMA Competition and Markets Authority Sweden privately held private equity (including portfolio companies) private equity (including portfolio companies) https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug UK21-68593
Focus Pharmaceuticals Ltd. and Focus Pharma Holdings Ltd. and Mercury Pharma Group Ltd. Nordic Capital Nordic Capital 921357 2022 20220203 competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation. agency action UK-CMA Competition and Markets Authority Sweden privately held private equity (including portfolio companies) private equity (including portfolio companies) https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug UK21-68595
Focus Pharmaceuticals Limited and Mercury Pharma Group Ltd. and Cinven Partners LLP et al. Nordic Capital Nordic Capital 1843380 2022 20220203 competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation. agency action UK-CMA Competition and Markets Authority Sweden privately held private equity (including portfolio companies) private equity (including portfolio companies) https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug UK21-68597
Focus Pharmaceuticals Limited and Mercury Pharma Group Ltd. and Concordia Investments (Jersey) Ltd. and Advanz Pharma Corp. Ltd. et al. Nordic Capital Nordic Capital 7288853 2022 20220203 competition-related offences
Warning: Undefined array key "offence_type" in /usr/home/goodjobsfirst/public_html/Live-UK-ViolationTracker/function.php on line 348
Alliance Pharmaceuticals Limited and Alliance Pharma plc, Focus Pharmaceuticals Limited, Focus Pharma Holdings Limited, Mercury Pharma Group Limited, Concordia Investment Holdings (UK) Limited, Concordia Investments (Jersey) Limited and Advanz Pharma Corp. Limited, Cinven Capital Management (V) General Partner Limited, Cinven (Luxco 1) S.A .r.l and Cinven Partners LLP, Lexon (UK) Limited and Lexon UK Holdings Limited, Medreich plc, Medreich Ltd, Meiji Seika Pharma Co. Ltd and Meiji Holdings Co. Ltd. were fined by the CMA following an investigation finding that the companies engaged in anti-competitive behaviour to increase the price of the drug prochlorperazine. Medreich's fine had a 40% leniency reduction for cooperating with the investigation. agency action UK-CMA Competition and Markets Authority Sweden privately held private equity (including portfolio companies) private equity (including portfolio companies) https://www.gov.uk/government/news/cma-fines-firms-over-35m-for-illegal-arrangement-for-nhs-drug UK21-68601
5